Rocket Lab shares slid about 9.0% in pre-open trading following the company's Q2 2026 earnings release, which was published after markets closed on Monday. The report presented a mixed set of results that triggered investor concern about near-term profitability.
On the top line, Rocket Lab posted record second-quarter revenue of $234 million, a 62% increase from the prior year and slightly above the analyst consensus of roughly $232 million. Despite the revenue beat, the company recorded an adjusted loss per share of $0.08, which missed expectations. Management's guidance for third-quarter GAAP gross margins came in at 29% to 31% - a marked shortfall relative to the Street's estimate of about 37.6% - and was the principal catalyst for the after-hours downturn that extended into the pre-market session.
Company commentary and subsequent market interpretation attributed much of the margin compression to a business-mix shift. Specifically, lower-margin satellite platform sales made up a larger portion of Space Systems revenue during the quarter, weighing on overall margin performance.
Several contextual factors amplified the market's reaction. Shares had rallied strongly in the run-up to the report, gaining roughly 27% in the prior week, which left the stock exposed to a sell-the-news response when results failed to meet the more optimistic outlook embedded in that rally. Additionally, investor concern about Rocket Lab's proposed $8 billion acquisition of Iridium gained prominence in the trading reaction. Market commentary noted potential dilution from about 41 million preferred shares included in third-quarter guidance, a detail that further pressured sentiment.
The pullback appeared to be company-specific. Broader market indices offered little offset; the S&P 500 was essentially flat and the Nasdaq was largely unchanged on the day, indicating that macro factors were not the primary driver. Peer companies in the space sector also faced scrutiny, reflecting the wider sensitivity of high-growth aerospace and satellite stocks to profitability timelines and margin expectations.
Anchoring investor concerns, Rocket Lab continues to report a substantial backlog of work - a record $2.36 billion - and progress on its Neutron launch vehicle development. Nevertheless, the earnings miss, the weaker-than-expected forward margin guide, and the stock's pre-earnings advance combined to prompt a repricing of near-term earnings prospects. As a result, shares moved toward their lowest levels since the selloff that followed the Iridium announcement.
Summary
Rocket Lab delivered record Q2 revenue but missed on adjusted EPS and provided Q3 GAAP gross margin guidance of 29%-31%, well below the Street's ~37.6% estimate. The stock fell roughly 9.0% pre-market as investors reacted to margin pressure tied to a larger mix of lower-margin satellite platform sales, a significant pre-earnings run-up (+27% the prior week), and concerns around the pending $8 billion Iridium acquisition, including about 41 million preferred shares embedded in guidance. The move occurred against an indifferent broader market and follows a record backlog of $2.36 billion and ongoing Neutron development progress.
Key points
- Record Q2 revenue of $234 million, up 62% year-over-year and slightly above the ~ $232 million analyst consensus.
- Adjusted loss per share of $0.08 missed expectations; Q3 GAAP gross margin guided to 29%-31% versus the Street estimate of ~37.6%.
- Share price vulnerability increased by a ~27% pre-earnings rally and by investor concerns tied to the $8 billion Iridium acquisition and about 41 million preferred shares reflected in guidance.
Risks and uncertainties
- Near-term margin pressure from a business mix shift toward lower-margin satellite platform sales - impacts aerospace and satellite-equipment suppliers.
- Potential dilution and integration uncertainty associated with the $8 billion Iridium transaction - relevant to M&A activity in the satellite communications sector.
- A high pre-earnings run-up left the stock exposed to a sell-the-news move, increasing volatility in the company's equity - affects equity investors and growth-oriented portfolios.